Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Royalty Pharma plc Director's Dealing 2022

Jun 30, 2022

30286_dirs_2022-06-29_686c621e-1fc7-4ac7-b899-f609634fde40.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Royalty Pharma plc (RPRX)
CIK: 0001802768
Period of Report: 2022-06-29

Reporting Person: RIGGS RORY B (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2022-06-29 Class A Ordinary Shares S 30000 $42.1746 Disposed 421712 Direct

Holdings (Non-Derivative)

Security Shares Ownership
Class A Ordinary Shares 85187 Indirect
Class A Ordinary Shares 15000 Indirect

Footnotes

F1: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.05 to $42.29 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.